Mylan Receives Final FDA Approval for the Generic Version of the Antidepressant Sarafem Pulvules Capsules

Mylan Inc. today announced that its subsidiary, Mylan Pharmaceuticals Inc., received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Fluoxetine Capsules USP, 10 mg and 20 mg.

The details can be read here.